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Abstract 
Objectives: To estimate prevalence, age-of-onset, gender distribution and identify correlates 
of lifetime psychiatric disorders in the São Paulo Metropolitan Area (SPMA). Methods: The São 
Paulo Megacity Mental Health Survey assessed psychiatric disorders on a probabilistic sample of 
5,037 adult residents in the SPMA, using the World Mental Health Survey Version of the Composite 
International Diagnostic Interview. Response rate was 81.3%. Results: Lifetime prevalence for 
any disorder was 44.8%; estimated risk at age 75 was 57.7%; comorbidity was frequent. Major 
depression, specific phobias and alcohol abuse were the most prevalent across disorders; anxiety 
disorders were the most frequent class. Early age-of-onset for phobic and impulse-control 
disorders and later age-of-onset for mood disorders were observed. Women were more likely to 
have anxiety and mood disorders, whereas men, substance use disorders. Apart from conduct 
disorders, more frequent in men, there were no gender differences in impulse-control disorders. 
There was a consistent trend of higher prevalence in the youngest cohorts. Low education level 
was associated to substance use disorders. Conclusions: Psychiatric disorders are highly prevalent 
among the general adult population in the SPMA, with frequent comorbidity, early age-of-onset 
for most disorders, and younger cohorts presenting higher rates of morbidity. Such scenario calls 
for vigorous public health action. 
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Prevalência em toda a vida, distribuição por idade e sexo e idade de início de 
transtornos psiquiátricos na área metropolitana de São Paulo, Brasil: Resultados do 
Estudo Epidemiológico de Transtornos Mentais São Paulo Megacity
Resumo
Objetivos: Estimar a prevalência, idade de início, distribuição por sexo e idade e identifica fatores 
correlacionados à morbidade psiquiátrica na Região Metropolitana de São Paulo (RMSP). Métodos: O 
Estudo Epidemiológico de Transtornos Mentais São Paulo Megacity avaliou transtornos psiquiátricos 
em uma amostra probabilística composta por 5.037 adultos (18+) residentes na RMSP, utilizando o 
Composite International Diagnostic Interview, versão World Mental Health Survey. A taxa global 
de resposta foi de 81,3%. Resultados: A prevalência de pelo menos um transtorno mental ao longo 
da vida foi de 44,8% e o risco estimado aos 75 anos de idade foi de 57,7%; comorbidade ocorreu 
com frequência. Depressão maior, fobias específicas e abuso de álcool foram os transtornos 
mais prevalentes; transtornos de ansiedade foi a classe de transtornos mais frequente. Fobias 
específicas e transtornos do controle de impulsos tiveram idade de início precoce, enquanto 
transtornos do humor tiveram início mais tardiamente. Mulheres apresentaram maior risco para 
transtornos do humor e de ansiedade, e homens para transtornos decorrentes do uso de álcool e 
drogas. Com exceção de transtornos da conduta, que foram mais frequentes em homens, não se 
observou diferenças de gênero na distribuição de transtornos do controle de impulso. Observou-se 
uma tendência consistente entre os diferentes transtornos de maiores taxas de morbidade nas 
coortes mais jovens. Baixa escolaridade mostrou-se associada a transtornos decorrentes do uso 
de álcool e drogas. Conclusão: Transtornos psiquiátricos na população geral adulta da RMSP são 
altamente prevalentes, com comorbidade frequente, idade de início precoce na maior parte dos 
transtornos avaliados, e taxas mais elevadas nas coortes mais jovens. Tal cenário suscita ações 
vigorosas de saúde pública.
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Introduction 
In an attempt to have more accurate information on the 
epidemiology of psychiatric disorders in different cultures, 
the WHO launched the World Mental Health (WMH) Surveys 
Initiative,1 with over 30 participating countries, using an 
extended and expanded version of the WHO-Composite 
International Diagnostic Interview (WMH-CIDI),2 based on 
diagnostic criteria from the International Classification of 
Diseases and Injuries 10th Revision (ICD-10)3 and the Diagnostic 
and Statistical Manual of Mental Disorders 4th edition (DSM-
IV).4 This manuscript is based on the São Paulo Megacity 
Mental Health Survey (SPMHS),5 carried out in conjunction 
with the WMH Surveys Initiative,5 which assessed the general 
population living in the São Paulo Metropolitan Area (SPMA). 
So far, few population-based surveys assessing psychiatric 
morbidity in the community have been conducted in Brazil. In 
the early 90’s, the Brazilian Multicentric Study of Psychiatric 
Morbidity was carried out in three cities, using screening ques-
tionnaires in two-phase surveys, reported lifetime prevalence 
rates of 31% in São Paulo, 42.5% in Porto Alegre and 50.5% in 
Brasília.6,7 Two later studies used fully structured diagnostic 
interviews (CIDI-1.1), yielding DSM-III-R and ICD-10 diagnoses. 
The São Paulo Epidemiologic Catchment Area Study (ECA)8,9 as-
sessed 1,464 residents of two boroughs in the city of São Paulo; 
lifetime and 12-month prevalence for at least one disorder 
were 33.1% and 18.5%, respectively. The Bambuí Health and 
Aging Study assessed 1,041 adults living in a small town in Minas 
Gerais.10-12 Lifetime prevalence of major depression and social 
phobia were 12.8% (17.0% among females and 7.3% in males) 
and 11.8% (females 13.0% and males 10.0%), respectively. 
These studies used rigorous sampling procedures. Nonetheless, 
the results were not generalizable to larger proportions of the 
general population, as the ECA study was limited to middle 
and upper socioeconomic neighborhoods, and the Bambuí 
survey only included  the assessment of depression and social 
phobia among the population of a small town in a rural area.
The SPMHS was designed to address these limitations and 
fulfill the gaps in knowledge regarding the epidemiology of 
mental disorders in the Brazilian general population, and 
produce information that can be compared to other regions 
of the world. In this report, we present lifetime prevalence 
estimates, projected lifetime risks, age-of-onset (AOO) dis-
tributions, intercohort variation, and sociodemographic cor-
relates of a wide range of DSM-IV disorders of adult residents 
in the São Paulo Metropolitan Area (SPMA), the largest urban 
area in South America. The SPMA is formed by 39 municipali-
ties and is among the five most populous areas in the world, 
with a population of 19.7 million people. The concentration of 
economic activities has attracted a large number of migrants 
from all Brazilian regions in the last decades, which have led 
to a decline in the overall quality of life, and increasing social 
and economic inequality in the region.
Methods
Study overview
As described in more detail elsewhere,5 the SPMHS is a cross-
sectional population-based epidemiological study of psychi-
atric morbidity, assessing a probabilistic sample of household 
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residents in the SPMA, aged 18 years and over. Respondents 
were selected from a stratified multistage clustered area prob-
ability sample of households, covering all 39 municipalities, 
without replacement. Data were collected between May/2005 
and April/2007 by trained lay interviewers, using the paper-
and-pencil version of the WMH-CIDI, which is composed by 
clinical and non-clinical sections, arranged in Part I and Part II. 
Core disorders (anxiety, mood, impulse-control and substance 
use disorders) and sociodemographic risk factors were assessed 
in all respondents (Part I sample). WMH-CIDI non-core clini-
cal modules as well as non-clinical sections were applied in 
a subsample composed by all core disorder cases and a 25% 
random sample of non-cases (Part II sample). A total of 5,037 
individuals received WMH-CIDI Part I and 2,942 were also given 
Part II. The global response rate was 81.3%.
The study was approved by the Ethical and Research 
Committee, School of Medicine/São Paulo University.
Diagnostic Assessment
Psychiatric diagnoses were based on the WMH-CIDI,2 a fully 
structured diagnostic interview. The paper-and-pencil version 
(PAPI) was translated and adapted into Brazilian Portuguese,13 
following international guidelines, and administered in face-
to-face household interviews by trained non-clinical inter-
viewers. DSM-IV diagnostic criteria were used and diagnoses 
include anxiety disorders [panic, agoraphobia, specific phobia, 
social phobia, generalized anxiety (GAD), post-traumatic stress 
(PTSD), obsessive-compulsive (OCD), and separation anxiety], 
mood disorders [major depression (MDD), dysthymia, bipolar 
I and II], impulse-control disorders [intermittent explosive, 
oppositional-defiant (ODD), conduct (CD), and attention-
deficit/hyperactivity (ADHD)], and substance use disorders 
(alcohol and drug abuse and dependence). PTSD and OCD were 
assessed in Part II; all other disorders in Part I. Organic exclu-
sion rules were used for the ascertainment of all diagnoses, 
and hierarchy rules were used for MDD, dysthymia, GAD and 
ODD. Retrospective information on AOO for all disorders was 
obtained using a series of questions designed to avoid recall 
bias or answers beyond the range. 
Sociodemographic correlates
Correlates of psychiatric morbidity assessed included: 1) 
cohort defined by age at interview 18-34, 35-49, 50-64, or 
65+ years; 2) gender as female or male; 3) education was 
defined according to the Brazilian school system, categorized 
as “0-4 years of education” (equivalent to: none - less than 
half primary school), “5-8 years” (more than half primary 
school - primary school complete), “9-11 years” (some high 
school - high school complete), or “12+ years of education” 
(some college or university - complete college or university). 
As it varies with time/age, education was also coded as a time-
varying predictor by assuming an orderly educational history, 
with 8 years of education corresponding to being a student up 
to age 14; other durations were based on this reference point. 
Statistical Analysis
Weights were applied to adjust differences in the probability 
of selection, differential non-response, and post-stratifying 
the final sample to approximate the year 2,000 population 
census regarding gender and age distribution,14 which were 
applied to data from the Part I sample. An additional weight 
adjusted for Part II selection - oversampling cases - was used 
to analyze Part II data. Weighting procedures are described in 
more detail elsewhere.5 Lifetime prevalence was estimated 
as the proportion of respondents who had ever fulfilled DSM-
IV diagnostic criteria for a given disorder up to their age at 
interview. AOO and projected lifetime risk as of age 75 years 
(PLR) were estimated using the two-part actuarial method 
contained in the SAS15 version 8.2.12, assuming a constant 
conditional risk of onset during a given year of life across age 
cohorts. Sociodemographic predictors were examined using 
discrete-time survival analysis with person-years as the unit of 
analysis.16 Sociodemographic variables that change over time 
(educational attainment) were treated as time-varying predic-
tors. Changes in the effects of predictors across cohort were 
evaluated by including interactions between predictors and 
cohort. Standard errors of prevalence estimates and survival 
coefficients were estimated with the Taylor series linearization 
method,17 using the Survey Data Analysis (SUDAAN)18 software. 
Multivariate significance tests were made with Wald c2 tests us-
ing Taylor series design-based coefficient variance-covariance 
matrices. Standard errors of lifetime risk were estimated using 
the jackknife repeated replication method19 in SAS. All results 
were based on the total sample (Part 1; N = 5,037 respondents) 
except OCD and PTSD as stated in the corresponding tables’ 
footnotes - where Part 2 sample was analyzed (N = 2,942). All 
tests were two-sided with significance set at 5%.
Results
Lifetime Prevalence: Age and Gender Distributions
The global prevalence of at least one DSM-IV lifetime dis-
order (Table 1) was 44.8% (SE 1.4), while 23.2% (SE 0.9) of 
respondents had two or more lifetime disorders and 13.4% 
(SE 0.7) had three or more. The most prevalent lifetime 
disorders were major depressive disorder (16.9%), specific 
phobia (12.4%) and alcohol abuse (9.8%). Anxiety disorders 
were the most prevalent class of disorders (28.1%), followed 
by mood disorders (19.1%), substance use disorders (11.0%) 
and impulse-control disorders (8.4%). For most disorders, 
prevalence rates varied significantly with age, generally 
with a steady increase from the youngest age groups and a 
decrease in the older group (65+). No age variation was seen 
for agoraphobia, PTSD, ODD, dysthymia and alcohol abuse.
Overall, prevalence rates were higher among women com-
pared to men (51.5% vs. 37.3%; OR = 1.8, 95%CI 1.4-2.2) (Table 1). 
Women were more likely to have had anxiety and mood disorders 
than men, with odds ratios around 3 for PTSD, agoraphobia, panic 
and depression. In turn, men were more likely to have substance 
use disorders than women (18.0% vs. 4.7%; OR = 4.4, 95%CI 3.3-
5.8), with significantly higher odds ratios (alcohol abuse 4.7; 
alcohol dependence 6.0; drug abuse 2.9; drug dependence 2.5). 
No gender differences were seen for impulse-control disorders, 
with the exception being for conduct disorders, which were more 
frequent in men (OR = 2.9; 95%CI 1.8-4.5).
Age-of-Onset (AOO)
The distributions of cumulative lifetime risk estimates were 
standardized and examined for selected percentiles (Table 2). 
The median AOO (50th percentile on the AOO distribution) 
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Table 1 Lifetime prevalence of DSM-VI WMH-CIDI disorders in the São Paulo Megacity Survey total sample, by age and gender
Age group Gender
Total 18-34 35-49 50-64 65+
c2#
Male Female
OR (95%CI)
% SE % SE % SE % SE % SE % SE % SE
Anxiety Disorders
Panic Disorder 1.7 0.2 1.1 0.2 2.5 0.5 2.2 0.7 1.0 0.6 12.3§ 0.9 0.18 2.5 0.38 2.9 (1.7- 5.0) &
Generalized Anxiety Disorder 3.7 0.3 2.5 0.5 4.8 0.5 4.1 0.7 4.5 1.6 8.9 2.6 0.34 4.6 0.37 1.8 (1.3-2.4) &
Social Phobia 5.6 0.4 6.5 0.6 5.2 0.6 5.2 0.7 2.0 0.4 58.5§§ 4.2 0.53 6.7 0.58 1.6 (1.2-2.3) &
Specific Phobia 12.4 0.6 10.2 0.9 14.6 1.1 16.3 1.2 8.9 1.3 34.9§§ 7.9 0.85 16.5 0.73 2.3 (1.8-2.9) &
Agoraphobia Without Panic 2.5 0.3 2.6 0.6 2.4 0.4 2.6 0.5 2.4 0.9 0.1 1.3 0.42 3.6 0.53 2.9 (1.4-6.1) &
Post-Traumatic Stress Disorder* 3.2 0.2 2.9 0.5 3.3 0.4 4.0 0.9 2.5 1.1 1.1 1.6 0.42 4.6 0.40 3.0 (1.6-5.7) &
Obsessive Compulsive Disorder* 6.7 0.5 7.3 0.9 6.7 1.1 7.6 1.0 2.4 0.8 78.8§§ 5.8 0.58 7.6 0.83 1.3 (0.98-1.8)
Separation Anxiety Disorder 7.7 0.4 8.6 0.6 8.2 0.9 6.8 1.0 2.7 0.9 34.6§§ 6.7 0.55 8.6 0.57 1.3 (1.04-1.6) &
Any Anxiety Disorder** 28.1 0.9 27.5 1.5 27.8 1.8 35.0 4.4 19.8 2.5 11.8§ 19.5 1.29 35.8 1.45 2.3 (1.9-2.8) &
Mood Disorders
Major Depressive Disorder 16.9 0.9 16.2 1.2 19.0 1.3 17.2 1.2 11.8 2.2 11.1§ 10.0 0.67 23.0 1.31 2.7 (2.3-3.1) &
Dysthymia 1.6 0.3 1.6 0.3 1.7 0.4 0.8 0.3 2.9 1.2 8.0 0.9 0.34 2.2 0.44 2.5 (1.5-5.3) &
Bipolar Disorder (I and II) 2.1 0.2 2.4 0.4 2.6 0.4 1.3 0.5 0.8 0.5 11.3§ 2.2 0.40 2.1 0.28 0.96 (0.6-1.5)
Any Mood Disorder 19.1 0.8 18.6 1.4 21.7 1.1 18.5 1.2 12.8 2.3 16.4§§ 12.3 0.82 25.2 1.25 2.4 (2.0-2.9) &
Impulse-Control Disorders
Oppositional Defiant Disorder 1.4 0.2 1.9 0.4 1.0 0.3 1.2 0.4 0.5 0.3 6.4 1.4 0.30 1.5 0.26 1.2 (0.7-1.9)
Conduct Disorder 2.1 0.2 2.8 0.5 1.8 0.3 0.9 0.4 1.3 0.9 19.0§§ 3.2 0.43 1.1 0.20 0.4 (0.2-0.5) &
Attention-Deficit/Hyperactivity Disorder 1.7 0.2 2.2 0.4 1.5 0.4 1.5 0.5 0.3 0.3 12.7§ 1.9 0.28 1.5 0.29 0.8 (0.5-1.3)
Intermittent Explosive Disorder 4.9 0.3 6.5 0.7 4.0 0.6 2.5 0.5 4.2 1.9 22.2§§ 4.7 0.49 5.1 0.51 1.1 (0.8-1.6)
Any Impulse-Control Disorder 8.4 0.4 11.1 0.7 6.8 0.7 4.9 0.8 6.0 2.1 44.6§§ 8.9 0.51 7.9 0.76 0.9 (0.7-1.2)
Substance Use Disorders
Alcohol Abuse 9.8 0.6 9.2 1.0 11.9 1.1 8.4 1.1 7.9 1.9 7.8 16.4 1.12 4.0 0.51 0.2 (0.2-0.3) &
Alcohol Dependence 3.3 0.3 2.4 0.5 4.6 0.6 3.7 0.8 2.1 0.6 12.3§ 5.8 0.69 1.0 0.15 0.2 (0.1-0.2) &
Drug Abuse 2.9 0.4 4.1 0.6 3.0 0.6 0.8 0.3 0.0 0.0 72.7§§ 4.4 0.62 1.6 0.34 0.3 (0.2-0.6) &
Drug Dependence 1.4 0.3 1.8 0.5 1.7 0.4 0.2 0.1 0.0 0.0 27.3§§ 2.0 0.47 0.8 0.22 0.4 (0.2-0.7) &
Any Substance Use Disorder 11.0 0.6 11.1 1.1 12.8 1.2 8.5 1.1 7.9 1.9 9.3§ 18.0 1.11 4.7 0.58 0.2 (0.2-0.3) &
Any Disorder
Any Disorder** 44.8 1.4 44.4 2.1 46.3 2.4 48.8 4.8 33.1 3.0 16.0§§ 37.3 2.08 51.5 1.83 1.8 (1.4-2.2) &
Two or more disorders** 23.2 0.9 23.6 1.5 24.1 1.8 23.7 2.5 16.8 2.6 11.1§ 20.3 1.56 25.8 1.24 1.4 (1.1-1.7) &
Three or more disorders** 13.4 0.7 14.0 1.3 15.0 1.2 12.2 1.2 6.2 1.5 31.3§§ 12.7 1.17 14.0 1.02 1.1 (0.8-1.5)
Abbreviations: WMH-CIDI, World Mental Health Survey version of the Composite International Diagnostic Interview; SE, Standard Error.
Part I sample size = 5,037; Part II sample size = 2,942.
* Part II disorder, estimated in the Part II sample.
** Includes Part I and Part II disorders. These summary measures were analyzed in the full Part II sample (N = 2,942).
§ Significant age difference (p ≤ 0.05); §§ Significant age difference (p ≤ 0.01).
# The c2 test evaluates the statistical significance of age-related differences in estimated prevalence; df = 3 for all disorders.
&Significant gender difference (p ≤ 0.05).
was earlier for anxiety disorders (age 13) and impulse-control 
disorders (age 14) compared to substance use disorders (age 
24) and mood disorders (age 36). The median AOO for anxiety 
disorders varied greatly, from around 40 years of age for GAD, 
panic and PTSD, to 14 and 8 years for social and specific phobia, 
respectively. In the other group disorders, the range of the 
median AOO was narrower: 31-51 for mood disorders, 8-16 for 
impulse-control disorders and 21-30 for substance use disorders.
The interquartile ranges (IQR) (number of years in be-
tween the 75th and the 25th percentiles in the AOO distribu-
tion) were smaller for impulse-control disorders (5 years 
for ODD, CD and ADHD; 9 years for IED) and drug abuse 
and dependence (age 8 and 10); and much wider for mood 
disorders (age 21-39) and some of the anxiety disorders 
(age >25 years for PTSD, OCD, agoraphobia, separation 
anxiety and GAD). 
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Projected lifetime risk
The distribution of standardized cumulative lifetime risk 
estimates produced a projection of lifetime risk at age 75 
(PLR) (Table 2), based on the AOO distributions. The PLR 
for any disorder was 12.9% higher than lifetime prevalence 
estimates reported in Table 1 (57.7% vs 44.8%), meaning that 
almost 80% of the new PLR onsets occurred to respondents 
that had already had a disorder. The individual disorders 
with the highest PLR were the same as with the highest 
prevalence rates (depression, specific phobia and alcohol 
abuse), with a two-fold increased risk for major depressive 
disorder (31.9%). Overall, the PLR was 5.7% higher for anxiety 
disorders, (with a PLR of 33.8% vs. 28.1% prevalence), 16.1% 
for mood disorders (35.2% vs. 19.1%), 0.5% for impulse-control 
disorders (8.9% vs 8.4%) and 3.8% higher for substance use 
disorders (14.8% vs. 11.0%).
Cohort Effects
Cohort was defined by age at interview, and dummy variables 
defining age groups 18-34 years, 35-49, 50-64, and 65+ were 
used to predict lifetime disorders using discrete-time survival 
analysis. These groups roughly corresponded to cohorts born 
in the years 1972 or later, 1957-1971, 1942-1956, and earlier 
than 1941. Cohort effect was significant for most disorders, 
Table 2 Age at selected percentiles on the standardized age-of-onset distributions of DSM-IV WMH-CIDI disorders, and 
projected lifetime risk at age 75 years
Age at Selected Age-of-Onset Percentiles (years) Projected Lifetime Risk at Age 
75 years, % (SE)5% 10% 25% 50% 75% 90% 95% 99%
Anxiety Disorders
Panic Disorder 11 14 24 37 43 62 65 65 3.0 (0.6)
Generalized Anxiety Disorder 14 17 26 41 61 65 73 73 8.5 (1.8)
Social Phobia 5 7 11 14 17 29 41 54 6.1 (0.4)
Specific Phobia 5 5 5 8 13 26 51 56 13.5 (0.7)
Agoraphobia Without Panic 5 9 13 19 41 54 67 67 3.3 (0.4)
Post-Traumatic Stress Disorder* 11 15 24 40 49 57 65 73 6.3 (0.6)
Obsessive Compulsive Disorder* 8 10 13 21 38 49 51 64 8.9 (0.8)
Separation Anxiety Disorder 6 7 11 19 37 59 68 68 9.8 (0.6)
Any Anxiety Disorder** 5 5 7 13 26 49 54 65 33.8 (1.6)
Mood Disorders
Major Depressive Disorder 14 17 24 38 51 63 65 69 31.9 (2.4)
Dysthymia 13 15 26 51 65 65 75 75 4.7 (1.4)
Bipolar I and I Disorder 13 15 19 31 40 62 62 68 3.3 (0.4)
Any Mood Disorder 13 16 23 36 50 62 65 72 35.2 (2.4)
Impulse-Control Disorders
Oppositional Defiant Disorder 5 5 8 10 13 16 16 19 1.4 (0.2)
Conduct Disorder 8 8 9 12 14 16 18 20 2.1 (0.2)
Attention-Deficit/Hyperactivity Disorder 5 5 5 8 10 13 13 16 1.7 (0.2)
Intermittent Explosive Disorder 8 12 14 16 23 31 39 47 5.4 (0.3)
Any Impulse-Control Disorder 5 7 9 14 18 25 31 43 8.9 (0.4)
Substance Use Disorders
Alcohol Abuse 16 18 20 26 39 49 53 57 13.8 (0.8)
Alcohol Dependence 18 19 21 30 41 55 55 61 5.2 (0.7)
Drug Abuse 15 17 19 21 27 34 39 51 3.5 (0.5)
Drug Dependence 15 18 20 24 30 39 41 51 1.7 (0.4)
Any Substance Use Disorder 16 17 20 24 36 48 51 57 14.8 (0.8)
Any Disorder
Any Disorder** 5 5 9 18 35 51 57 65 57.7 (2.5)
Abbreviations: WMH-CIDI, World Mental Health Survey version of the Composite International Diagnostic Interview; SE, Standard Error.
Part I sample size = 5,037; Part II sample size = 2,942.
* Part II disorder, estimated in the Part II sample.
** Includes Part I and Part II disorders. These summary measures were analyzed in the full Part II sample (N = 2,942).
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with a consistent positive association between recency of 
cohort and odds ratio of onset (Table 3). The largest cohort 
effects were associated with drug dependence, bipolar disor-
der, MDD and drug abuse. The only disorder with a significant 
negative cohort effect was specific phobia. 
A cohort model (Table 4) was elaborated to evaluate 
whether inter-cohort differences decreased significantly 
with increasing age, a pattern that might be expected either 
if lifetime risk was actually constant across cohorts but ap-
peared to vary with cohort due to onsets occurred earlier 
in more recent rather than in older cohorts (either due to 
secular changes in environmental risk factors or age-related 
differences in AOO recall accuracy) or if differential mortality 
had an increasingly severe effect on sample selection bias 
with increasing age. The actual distribution of AOO among 
those with the various disorders (any mood, any anxiety, any 
substance) was used, and this distribution was broken into 
tertiles to create the categories “early”, “middle” and “late” 
AOO. For anxiety disorders, early AOO are 4-6 years, middle 
is 7-13, and late is 14+; for mood disorders are 4-18, 19-31, 
and 32+, respectively; and for substance use disorders are 
4-18, 19-23, and 24+, respectively. Impulse-control disorders 
were not included due to small numbers and a narrow AOO 
time window. The cohort model shown in Table 4, examining 
differences separately for first onsets across life course, com-
pares odds of onset within each period of life (early, middle 
and late) across cohorts, to test if the inter-cohort effect 
varies as a function of AOO of disorders, indirectly monitoring 
Table 3 Cohort (age at interview) as a predictor of lifetime risk of DSM-VI WMH-CIDI disorders in the São Paulo Megacity Survey □
Lifetime Risk by Age at Interview (Years) Compared With Respondents Aged  
≥ 65 years, Odds Ratio (95% CI) c2¥ p¥
18-34 35-49 50-64
Anxiety Disorders
Panic Disorder 4.1 (0.7-23.0) 4.6 (0.9-23.6) 2.6 (0.6-10.9) 3.8 0.287
Generalized Anxiety Disorder 3.0§ (1.1-7.9) 2.7§ (1.3-5.9) 1.4 (0.6-3.1) 14.7 0.002
Social Phobia 3.9§ (2.4-6.2) 2.8§ (1.9-4.3) 2.6§ (1.5-4.7) 39.7 < 0.001
Specific Phobia 1.3 (0.9-1.9) 1.8§ (1.3-2.6) 2.0§ (1.3-3.0) 25.4 < 0.001
Agoraphobia Without Panic 2.0 (0.7-5.7) 1.4 (0.6-3.2) 1.2 (0.5-3.0) 3.7 0.293
Post-Traumatic Stress Disorder* 7.1§ (2.1-24.5) 3.3§ (1.3-8.3) 2.0 (0.6-6.1) 23.5 < 0.001
Obsessive Compulsive Disorder* 5.9§ (3.1-11.4) 4.0§ (2.0-8.1) 3.5§ (1.9-6.2) 32.5 < 0.001
Separation Anxiety Disorder 7.4§ (3.5-15.6) 5.3§ (2.4-11.5) 3.4§ (1.5-7.7) 43.3 < 0.001
Any Anxiety Disorder* 2.1§ (1.5-2.9) 1.8§ (1.3-2.5) 2.1§ (1.3-3.5) 20.2 < 0.001
Mood Disorders
Major Depressive Disorder 13.9§ (9.7-19.8) 5.9§ (4.2-8.2) 2.4§ (1.7-3.3) 246.5 < 0.001
Dysthymia 3.7§ (1.6-8.3) 2.3 (0.9-5.5) 0.5 (0.2-1.3) 37.7 < 0.001
Bipolar I and I Disorder 14.8§ (4.2-51.3) 6.8§ (2.1-22.0) 2.3 (0.6-8.9) 25.5 < 0.001
Any Mood Disorder 13.2§ (9.3-18.9) 5.9§ (4.4-8.0) 2.4§ (1.7-3.2) 244.9 < 0.001
Impulse-Control Disorders
Oppositional Defiant Disorder 3.7 (0.8-16.1) 1.9 (0.5-6.9) 2.3 (0.5-9.9) 5.5 0.142
Conduct Disorder 2.2 (0.5-9.3) 1.4 (0.3-6.1) 0.7 (0.1-6.5) 18.2 < 0.001
Attention-Deficit/Hyperactivity Disorder 6.8 (0.8-56.6) 4.5 (0.5-38.0) 4.6 (0.6-35.3) 4.8 0.187
Intermittent Explosive Disorder 2.0 (0.7-5.9) 1.0 (0.4-2.6) 0.6 (0.2-1.8) 26.6 < 0.001
Any Impulse-Control Disorder 2.2§ (1.0-4.6) 1.2 (0.6-2.4) 0.8 (0.3-2.0) 41.6 < 0.001
Substance Use Disorders
Alcohol Abuse 2.8§ (1.5-5.2) 2.1§ (1.2-3.7) 1.1 (0.6-2.2) 55.9 < 0.001
Alcohol Dependence 3.5§ (1.4-8.8) 3.4§ (1.7-6.8) 2.0 (0.9-4.5) 17.8 < 0.001
Drug Abuse 9.5§ (3.9-22.8) 4.3§ (1.5-12.9) 1.0 (1.0-1.0) 58.3 < 0.001
Drug Dependence 16.3§ (6.7-39.7) 8.4§ (3.1-22.4) 1.0 (1.0-1.0) 43.2 < 0.001
Any Substance Use Disorder 3.2§ (1.6-6.2) 2.2§ (1.2-3.9) 1.1 (0.6-2.3) 82.2 < 0.001
Any Disorder
Any Disorder** 2.9§ (2.2-3.7) 2.2§ (1.8-2.8) 1.9§ (1.3-2.9) 76.1 < 0.001
Abbreviations: WMH-CIDI, World Mental Health Survey version of the Composite International Diagnostic Interview; OR, Odds Ratios; CI, Confidence Interval.
Part I sample size = 5,037; Part II sample size = 2,942.
□ Based on discrete-time survival models with person-years as the unit of analysis. Time intervals were used as controls in this model.
* Part II disorder, estimated in the Part II sample (N = 2,942).
** Includes Part I and Part II disorders. These summary measure were analyzed in the full Part II sample (N = 2,942).
§ Significant difference compared with those aged 65 years or older (p ≤ 0.05, 2-sided test).
¥ Testing for global inter-cohort differences (3 degrees of freedom).
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differential recall or mortality. Inter-cohort differences with 
higher risks for younger cohorts remain significant for most 
disorders (apart from early onset anxiety disorders) inde-
pendently of time of disorder onset and age at interview.
Sociodemographic predictors
Several sociodemographic variables were significantly as-
sociated with lifetime risk of DSM-IV WMH-CIDI disorders 
(Table 5). Women had significantly higher risk of anxiety 
and mood disorders compared to men, while male gender 
was a predictor of substance use disorders (OR = 3.8 95%CI 
3.3-5.0). Overall, there was no association between gender 
and impulse-control disorders (OR = 0.8), although gender 
differences for individual disorders were seen in Table 1, 
with higher prevalence of CD among men (OR = 5.0). Low 
education level was associated only with substance use 
disorders. Younger ages were significant predictors for all 
disorder classes (cohort effects). The associations with 
gender and education were also examined by age, to test 
if there were variations in predicting psychiatric disorders 
across cohorts (results available upon request). Significant 
interactions between gender and age were found only in 
predicting substance use disorders, as female rates, though 
still much smaller, are becoming more similar to male´s in 
more recent cohorts [OR = 0.32 (95%CI 0.21-0.48) for age 
18-34; OR = 0.22 (0.13-0.37) 35-49; OR = 0.101 (0.04-0.25) 
50-64; OR = 0.15 (0.02-1.01) for 65+ years of age].
Table 4 Variation in the effects of cohort (age at interview) in predicting lifetime risk of DSM-VI WMH-CIDI Disorders in the São 
Paulo Megacity Survey □
Lifetime risk by age at interview (years), Odds Ratio (95%CI)
Age of OnsetA
Early Middle Late
Anxiety Disorders
Age at Interview (years)
  18-34 1.4 (0.7-2.6) 3.0* (1.5-6.0) 3.0* (1.8-5.2)
  35-49 1.7 (0.96-3.08) 2.5* (1.2-5.3) 1.8 (0.9-3.5)
  50-64 2.1 (0.9-5.2) 3.2* (1.4-7.2) 1.9 (0.99-3.6)
  65+ 1.0 1.0 1.0
c2 5.7 (df = 3, p = 0.129) 12.6 (df = 3, p = 0.006) 24.1 (df = 3, p ≤ 0.001)
Global c2¥ 22.34(df = 6, p = 0.001)
Mood Disorders
Age at Interview (years)
  18-34 8.8* (3.2-24.5) 26.3* (9.2-75.2) 16.7* (7.1-39.5)
  35-49 4.2* (1.5-12.1) 10.9* (3.8-30.8) 5.9* (4.1-8.5)
  50-64 2.4 (0.8-7.2) 3.7* (1.2-11.1) 2.3* (1.6-3.2)
  65+ 1.0 1.0 1.0
c2 35.2 (df = 3, p ≤ 0.001) 73.2 (df = 3, p ≤ 0.001) 101.8 (df = 3, p ≤ 0.001)
Global c2¥ 10.18 (df = 6, p = 0.117
Substance Use Disorders
Age at Interview (years)
  18-34 50.5* (6.6-385.8) 1.6 (0.5-4.7) 2.1 (0.9-5.2)
  35-49 23.7* (3.2-176.4) 1.4 (0.6-3.2) 2.0 (0.8-4.5)
  50-64 9.5* (1.04-87.2) 0.8 (0.3-2.2) 1.1 (0.5-2.7)
  65+ 1.0 1.0 1.0
c2 26.1 (df = 3, p ≤ 0.001) 9.0 (df = 3, p = 0.029) 8.3 (df = 3, p = 0.040)
Global c2¥ 13.06 (df = 6, p = 0.042)
Abbreviations: WMH-CIDI, World Mental Health Survey version of the Composite International Diagnostic Interview; CI, Confidence Interval.
□ Based on discrete-time survival models with person-years as the unit of analysis. Total sample models evaluated the significance of interactions between 
cohort and person-years in the lives of respondents. This was not done for impulse-control disorders because the vast majority of such disorders have onsets in 
a very narrow time window. Model includes time intervals and gender as controls. All analysis were carried out using the Part II sample (n = 2,942).
A For anxiety disorders, early onset is 4 to 6 years of age, middle onset is 7 to 13, and late onset is 14+; for mood disorders is 4-18, 19-31, 32+, 
respectively; and for substance use disorders is  4-18, 19-23, 24+, respectively.
* Significant difference compared with the cohort born before 1941 –those aged 65 years or older (p ≤ 0.05, 2-sided test).
¥ Testing for global inter-cohort differences (6 degrees of freedom: test for the difference between onsets at different ages for different cohorts, all 3 
categories of age of onset in the late onset are the reference group).
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Gender differences in anxiety and mood disorders did not 
differ across cohorts. For impulse-control disorders, a higher 
risk was observed among men only among the oldest cohort; 
there was also significant interaction between education 
and age at interview, with stronger negative associations in 
more recent cohorts.
Discussion
Lifetime prevalence and projected risk [biro:tit2]
This study showed that mental disorders are common in the 
SPMA, with 44.8% of the general adult population having 
experienced at least one disorder at some time in their lives 
prior to the interview, and 57.5% are projected to experience 
a mental disorder by the age of 75 years. These estimates are 
amongst the highest reported in the world. Higher levels of 
psychiatric morbidity are associated with poor living condi-
tions in large urban conglomerates,20 as social groups living in 
adverse situations under chronic stress would be more likely to 
present mental disorders. Social exclusion, amplified by poor 
access to education, was reported to be an important risk 
factor for mental disorders.21 According to the map of social 
exclusion in the city of São Paulo,22 89.0% of its population 
live below desirable standard of living conditions: aside from 
low income, there is poor access to education, sanitation, and 
housing, among other services. Moreover, social tension and 
urban violence may arise from inequity, due to poverty and 
wealth extremes being sharing space within the city.22 
Nevertheless, the prevalence estimates reported herein 
are high compared to those found in the São Paulo Catchment 
Area Study8,9 (33.1%), a previous survey conducted in two 
boroughs from the catchment area of a large hospital com-
plex in the city of São Paulo. Aside from the fact that fewer 
psychiatric disorders were assessed, differences could also be 
explained by the higher socioeconomic status of the population 
studied, with better housing and living conditions, and easier 
access to health services.8,9 Albeit using different methodol-
ogy, comparable lifetime prevalence estimates were found 
in Brasília (50.5%) and Porto Alegre (42.5%) in the Brazilian 
Multicentric Study.6,7 When compared to estimates obtained 
in other WHO-WMH Survey Initiative participating countries, 
using comparable methodology,23-34 the overall prevalence 
estimate for any lifetime disorder in the SPMA (44.8%) was 
only exceeded by that obtained in the National Comorbidity 
Survey Replication (NCS-R) conducted in the U.S. (47.4%), and 
followed closely by the rates in New Zealand (39.3%), Colombia 
(39.1%), France (37.9%) and Ukraine (36.1%). However similar 
the methodological procedures might have been, the only two 
countries that used all WMH-CIDI clinical modules and, thus, 
assessed a wider range of mental disorders were the U.S. and 
Brazil, which can partly explain the higher rates. For instance, 
New Zealand did not assess OCD, separation anxiety (either 
adult or childhood) and none of the impulse-control disorders, 
Table 5 Sociodemographic Correlates of Lifetime DSM-VI WMH-CIDI Disorders in the São Paulo Megacity Survey □
Lifetime Risk, Odds Ratio (95%CI)
Any Anxiety Disorder Any Mood Disorder Any Impulse-Control Disorder Any Substance Use Disorder
Gender
  Female 2.2* (1.8-2.7) 2.5* (1.8-3.4) 0.8 (0.6-1.1) 0.26* (0.2-0.3)
  Male 1.0 1.0 1.0 1.0
Gender c2 60.8 (df = 1, p ≤ 0.001) 34.4 (df = 1, p ≤ 0.001) 1.6 (df = 1, p = 0.207) 97.5 (df = 1, p ≤ 0.001)
Age at Interview
  18-34 2.3* (1.6-3.4) 12.9* (7.9-21.1) 2.5* (1.1-5.6) 2.6* (1.2-5.5)
  35-49 2.0* (1.4-3.0) 5.9* (3.6-9.6) 1.3 (0.6-2.7) 1.7 (0.9-3.3)
  50-64 2.6* (1.6-4.2) 2.8* (1.7-4.5) 0.9 (0.4-2.3) 0.7 (0.4-1.4)
  65+ 1.0 1.0 1.0 1.0
Age c2 24.5 (df = 3, p ≤ 0.001) 123.3 (df = 3, p ≤ 0.001) 43.3 (df = 3, p ≤ 0.001) 65.6 (df = 3, p ≤ 0.001)
Education§
  Current Student 1.7 (0.8-3.5) 1.1 (0.6-2.1) 2.8 (0.7-11.3) 1.4 (0.8-2.5)
  0-4 years 1.5 (0.6-3.5) 1.1 (0.7-1.7) 3.4 (0.9-12.4) 2.0* (1.1-3.5)
  5-8 years 3.0* (1.1-8.3) 1.3 (0.8-2.3) 3.8 (0.8-17.7) 3.1* (1.6-5.9)
  9-11 years 1.2 (0.6-2.5) 1.1 (0.7-1.8) 1.9 (0.4-9.1) 1.3 (0.7-2.6)
  12+ years 1.0 1.0 1.0 1.0
Education c2 7.1 (df = 4, p = 0.133) 1.3 (df = 4, p = 0.865) 8.5 (df = 4, p = 0.075) 27.4 (df = 4, p ≤ 0.001)
Abbreviations: WMH-CIDI, World Mental Health Survey version of the Composite International Diagnostic Interview; CI, Confidence Interval.
□ Based on discrete-time survival models with person-years as the unit of analysis. All analysis were carried out using the Part II sample (n = 2,942).
* Significant difference (p ≤ 0.05, 2-sided test).
§ Time-varying predictor.
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and France, as well as other Western European countries, did 
not assess OCD, separation anxiety, drug abuse or dependence, 
bipolar disorder, dysthymia and intermittent explosive disor-
der. Indeed, there is a wide variation in the estimated lifetime 
prevalence of mental disorders in the WMH surveys, possibly 
more than what could be explained only by such differential 
assessments. Furthermore, there is great variation in the 
prevalence estimates of individual disorders, which could be 
due to the assumption that the WMH-CIDI does not adequately 
or consistently capture psychopathological syndromes in dif-
ferent cultures35,36, as the lowest prevalence rates were found 
in non-Western countries (Nigeria 12%, China 13.2% and Japan 
18.1%), with the exception of Israel with an overall prevalence 
rate of 17.6% (but only including the assessment of mood and 
substance use disorders, and few anxiety disorders). Finally, 
the lifetime prevalence estimate of OCD in our study was high 
(6.7%, SE = 0.5), compared to the NCS-R (2.3%, SE = 0.3).37 
Although the instrument used was the same, it was found to 
show little sensitivity in the NCS-R, and the skip patterns were 
modified to keep respondents in the section, answering more 
questions, with a greater probability of picking up otherwise 
false-negatives, or conversely, identifying more false-positives. 
This issue will be further investigated by analyzing the SPMHS 
clinical reappraisal data collected in 780 subjects using the 
SCID for DSM-IV.38 This reappraisal study may also be able to 
address the accuracy of the Brazilian WMH-CIDI in identifying 
cases in the general population. Since the CIDI is based on the 
assessment of symptoms that compose diagnostic criteria for 
psychiatric disorders, it may have detected mild cases with no 
clinical relevance, contributing to the high prevalence rates.
Nevertheless, widely consistent with earlier prevalence 
studies and most WHO-WMH surveys, anxiety disorders are 
the most frequent class and mood disorders are also com-
mon, with major depressive disorder, phobias and alcohol 
abuse being the most prevalent individual disorders. The 
gender distribution observed in this study also replicates 
the general findings, with women having more anxiety and 
mood disorders and men having higher rates of substance 
use disorder. However, there were no gender differences for 
impulse-control disorders, reported to be higher among men 
in most previous studies (Colombia, Mexico, NCS-R, France, 
Germany, Italy, China); the only exception being conduct 
disorders, which were 3 times more prevalent among men. 
Lifetime comorbidity was also quite common, with the sum 
of prevalence rates for all disorders almost doubling the preva-
lence for any disorder (91.6% vs. 44.8%) and 21.8% higher across 
the four disorder classes (66.6%). Within class, co-occurrence 
was higher among anxiety disorders (43.5% vs. 28.1%).
Finally, it is worth noting that non-affective psychoses 
were not assessed in this survey, which may not be highly 
prevalent, but are, nevertheless, usually severe, greatly 
impairing and associated with enormous social and family 
burden. Although questions regarding psychotic-like experi-
ences were asked, these data were not used herein.
Age-of-Onset
Standardized AOO distributions in our study showed strong 
consistency with most WMH surveys, with impulse-control 
disorders having the earliest AOO distribution, especially 
attention-deficit and oppositional defiant disorders. Anxiety 
disorders also followed the same pattern of other countries, 
falling into two distinct sets, with phobias and separation 
anxiety having early AOO, while GAD, panic disorder and PTSD 
having a much later AOO, similar to those in mood disorders. 
For substance use disorders, it is also consistent with the 
international pattern, with earlier AOO for drug abuse and 
dependence and later for alcohol dependence. Although the 
WHO-WMH version of the CIDI included questions encourag-
ing precision in answering AOO of symptoms and syndromes, 
the possibility of recall bias has to be considered, especially 
as a function of age at interview, with older respondents 
tending to have more imprecise recall of onset of long-time 
past events. As co-morbidity is common, one may argue 
that the bulk of disorders occur within the first decades of 
life and that late-onset disorders largely occur as secondary 
comorbid conditions. 
It is worthwhile to emphasize that the results reported 
herein corroborate the increased burden associated with 
mental disorders, as they occur early in life, have a long 
course, are associated with disability and often present with 
other mental comorbid disorders,38,39 distinct from chronic 
physical disorders, which mostly occur later in life.
Projected lifetime risk
The projected lifetime risk of having presented any DSM-IV 
lifetime disorder at age 75 is 28.8% higher than estimated 
lifetime prevalence, with almost 57.7% of the population 
having had at least one disorder. These projections were also 
calculated for other WMH survey countries35 and are the high-
est so far, closely followed by the U.S.A. (55.3%), Colombia 
(55.3%), Ukraine (48.9%), New Zealand (48.6%), South Africa 
(47.5%) and France (47.2%). The highest proportional increase 
was observed in countries exposed to sectarian violence 
(Israel 68.8%, Nigeria 62.5% and South Africa 56.8%). There 
was no strong difference in proportional increase in devel-
oped countries (17%-49%) compared to developing countries 
(28%-41%),35 including Brazil (28.8%).
The PLR was estimated on the assumptions of constant 
conditional risk of first onset of a disorder in a given year 
of life, ascertained among people with different ages at 
interview. Since there were cohort differences in lifetime 
prevalence, the PLR for younger cohorts is likely to be un-
derestimated, as it was based on the assumption of constant 
inter-cohort conditional risk. Since the sum of individual dis-
order projected prevalences within disorder classes is much 
higher than the overall PLR estimate, it also corroborates 
that late-onset disorders are likely to be onsets of secondary 
comorbid conditions. These considerations, coupled with the 
magnitude of such projections point out to the important 
role of early treatment of early-onset disorders, in order 
to prevent later comorbidity and more severely impairing 
conditions, as well as greater individual and societal burden 
which has tremendous public health implications.
Cohort Effects
Previous findings have already pointed out that younger 
cohorts may present higher rates of psychiatric morbidity.38 
This was indirectly estimated from cross-sectional data using 
retrospective information on AOO of assessed disorders. The 
same approach was used in estimating the cohort effects in the 
WMH surveys, using discrete-time survival analysis to predict 
onset of disorders across age groups, similar to that of this 
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study. Information available from 17 WHO-WMH participating 
countries showed that younger cohorts presented higher rates 
of anxiety disorders in all but three countries (Italy, Ukraine 
and China), of mood disorders in all countries but South Africa, 
and of substance use disorders in all but three countries (South 
Africa, Italy and Japan), whereas in most countries there were 
no observed cohort effects for impulse-control disorders (ex-
cept for Mexico). Similar results were obtained in our study, 
and cohort differences remained significant after controlling 
for time of disorder onset in the lifespan and age at interview. 
We did not test, however, for impulse-control disorders, as the 
numbers were too small and the age of onset range too narrow. 
Although only prospective studies can directly and accurately 
appraise cohort effects, it can be persuasively argued that we 
were successful in obtaining a fine approximation.
Sociodemographic correlates
Our findings are similar to most previous population-based 
reports regarding gender and age predicting mental disorders, 
as discussed above. When gender and age interactions were 
explored, new features were seen only for substance use dis-
order, with women rates of abuse and dependence increasing 
in more recent cohorts, approximating male patterns. Similar 
behavior was observed in impulse-control disorders, where 
gender differences were only seen in older cohorts. It is 
worth noting that these analyses were performed only taking 
into account disorder classes (i.e. anxiety, mood, etc), and 
not individual disorders. These findings are consistent with 
international reports.23-35,38 The association of low social class 
with poor mental health was not seen in this report, as far as 
the proxy for social class used (education) could demonstrate, 
which was only associated with substance use disorders. It is 
possible that education favors better reporting on psychiatric 
symptoms. Respondents with low education might be less 
capable of understanding long and complex research question-
ing, while underestimating the risk posed by the symptoms. 
Other socioeconomic correlates, such as personal and family 
income and occupational history, will be further examined.
Limitations of the study
Finally, the results reported in this paper should be interpreted 
taking into account several limitations. First, there is no clini-
cal gold-standard assessment to check the consistency of the 
diagnoses produced by the WMH-CIDI on the disorders assessed 
in this study. The concordance of the WMH-CIDI with the 
Structured Clinical Interview for DSM-IV (SCID)40 was found to 
be unbiased for 12-month WMH-CIDI prevalence estimates, but 
generally conservative for lifetime disorders.41 The reliability of 
a previous Brazilian version of the CIDI (CIDI 2.1) showed high 
Kappa values for lifetime disorders, ranging from 076 (for OCD) 
to 1.0 (for alcohol and substance-related disorders).42 Further 
considerations also point out that the prevalence estimates 
reported herein, however high, are likely to be conservative. 
Not all psychiatric disorders were assessed by the WMH-CIDI and, 
besides, systematic error might have occurred. Embarrassing 
behaviors or emotional contents, including psychological suffer-
ing or symptoms, suicide-related conduct, and substance abuse 
among others, are likely to be underreported, especially in 
cross-sectional assessments,43 and even more so in non-clinical 
interviews conducted within the respondent´s household. Recall 
bias may also impair the accuracy of retrospective information, 
especially when the occurrence is likely to have happened long 
before the interview. Although the WMH-CIDI was rebuilt tak-
ing into consideration a series of strategies to minimize recall 
bias and information bias while approaching sensitive issues or 
preceding information,2 it is unlikely that they were completely 
ruled out. Selection bias leading to underestimating the true 
general population prevalence rates also likely occurred, as 
people with mental illness are less likely to be truly represented 
in the adopted sampling frame (excluding the homeless and 
individuals living in institutions), more likely to be exclude from 
selection as ineligible to participate (due to impeding physical, 
mental or cognitive conditions) or may present differential 
mortality. Moreover, people with mental problems are known 
to be more reluctant to participate in epidemiological surveys 
of this sort.44,46 It is not possible, however, to evaluate this 
hypothesis and determine its impact, as information on non-
responders was limited to the household listing (age, gender, 
and family relation to household informant). All these plausible 
biases were, therefore, likely to have yielded conservative rates 
of psychiatric morbidity, according to the adopted system of 
classification.
Conclusion
The SPMHS, the Brazilian component of the WHO-WMH Surveys 
Consortium, provides the first population-based estimates of 
lifetime prevalence and age-of-onset of DSM-IV disorders in 
Brazil. It is the first epidemiological study providing popula-
tion-based information on several disorders in Brazil, such 
as of post-traumatic stress disorder, obsessive-compulsive 
disorder, separation anxiety disorder, dysthymia, as well as 
on all impulse-control disorders (oppositional-defiant, con-
duct, attention-deficit and intermittent explosive disorders). 
Although the lifetime prevalence estimates and projected 
risks are likely to be conservative, almost half of the popu-
lation met the DSM-IV criteria for one or more disorders at 
some point in their lives prior to the interview and almost 60% 
will do so by the age of 75 years. Major depression, specific 
phobias and alcohol abuse are the most common individual 
disorders, and anxiety disorders are the most frequent class 
of disorders. Women are more likely to have anxiety and 
mood disorders than men, and men are more likely to present 
substance use and conduct disorders compared to women. 
More recent cohorts seem to have higher rates of psychiatric 
morbidity compared to older cohorts. Most primary disorders 
have early AOO, with later co-occurrence of comorbid condi-
tions, progressing to more severe and impairing outcomes, 
contributing to long-lasting disability and enormous personal 
and societal burden. The analyses on clinical significance 
show that even milder disorders are associated with impair-
ment and the lack of adequate treatment is the rule, even 
for more severe disorders.47,48 Therefore, the present results 
may be point toward a cumbersome reality: there may be 
many more people in need of care than treatment resources 
which can be made available or which the health budget can 
provide. Even considering that not all mental disorders are 
cost-effectively treatable and that not all milder cases need 
treatment, the deficit of resources will probably still be huge, 
especially assuming younger cohorts will continue to present 
higher rates of morbidity. These considerations can be used 
to orient public health efforts in implementing preventive 
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strategies that target individuals at risk, averting otherwise 
future illness, and focusing on early detection and intervention 
of mental disorders. Aiming at preventing the progression of 
primary disorders and the late-onset occurrence of comorbid 
conditions will allow to decrease the burden associated with 
mental disorders in the long run.
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